• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Immunomedics submits LeukoScan to FDA

Article

Immunomedics of Morris Plains, NJ, has submitted a biologies licenseapplication to the Food and Drug Administration for approval ofLeukoScan, a technetium-99m-labeled monoclonal antibody-basedagent for imaging bone infection. LeukoScan received a

Immunomedics of Morris Plains, NJ, has submitted a biologies license

application to the Food and Drug Administration for approval of

LeukoScan, a technetium-99m-labeled monoclonal antibody-based

agent for imaging bone infection. LeukoScan received a positive

recommendation from Europe's Committee for Proprietary Medicinal

Products in October (SCAN 10/23/96).

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.